Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 651 to 660 of 2208 total matches.

Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK1) receptor antagonist netupitant ...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK1) receptor antagonist netupitant and the serotonin-3 (5-HT3) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK1 receptor antagonist to be approved in the...
Med Lett Drugs Ther. 2015 Apr 27;57(1467):61-3 | Show Introduction Hide Introduction

Umeclidinium (Incruse Ellipta) for COPD

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
-adrenergic agonist vilanterol as Anoro Ellipta.1 Pronunciation Key Umeclidinium: ue mek" li din' ee um Incruse ...
The FDA has approved Incruse Ellipta (GSK), a single-agent inhaler containing the long-acting anticholinergic umeclidinium, for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium was initially approved in combination with the long-acting beta2-adrenergic agonist vilanterol as Anoro Ellipta.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):63-4 | Show Introduction Hide Introduction

Glyxambi - A New Combination for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
A1c) by 0.5%-1.5%. In the absence of contraindications, metformin is the preferred firstline agent.1 ...
The FDA has approved Glyxambi (Boehringer Ingelheim/Lilly), a fixed-dose combination of empagliflozin (Jardiance) and linagliptin (Tradjenta), for oral treatment of type 2 diabetes in adults. It is the first combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor to be approved in the US.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):65-6 | Show Introduction Hide Introduction

In Brief: Mechlorethamine Gel (Valchlor) for Cutaneous T-Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
daily for up to 1 year. Response rates, based on a composite assessment of index lesion severity, were ...
The FDA has approved a 0.016% gel formulation of the nitrogen mustard mechlorethamine (Valchlor – Actelion) for second-line topical treatment of patients with stage IA or IB mycosis fungoides, the most common type of cutaneous T-cell lymphoma. Topical nitrogen mustard has been used off-label for decades for this indication, usually as a pharmacy-compounded ointment, but no clinical trials evaluating its efficacy and safety have been done. Mechlorethamine is also available in an injectable formulation (Mustargen – Recordati) for the same and other indications.FDA approval of Valchlor was...
Med Lett Drugs Ther. 2015 Apr 27;57(1467):e66 | Show Introduction Hide Introduction

Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
by the FDA for PTCL. The first was the antifolate drug pralatrexate (Folotyn),1 which was followed ...
The FDA has approved belinostat (Beleodaq – Spectrum), an IV histone deacetylase (HDAC) inhibitor, for treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is the third IV drug approved by the FDA for PTCL. The first was the antifolate drug pralatrexate (Folotyn), which was followed by the HDAC inhibitor romidepsin (Istodax). Vorinostat (Zolinza), an oral HDAC inhibitor, is FDA-approved for treatment of cutaneous T-cell lymphoma.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):e66-67 | Show Introduction Hide Introduction

Pomalidomide (Pomalyst) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
on days 1-21 of a 28-day cycle alone or combined with 40 mg/week of dexamethasone. Progression ...
The FDA has approved pomalidomide (Pomalyst – Celgene), an oral thalidomide analog, for treatment of patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide (Revlimid) and bortezomib (Velcade) and whose disease had progressed on or within 60 days of completion of the last therapy.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):e66-67 | Show Introduction Hide Introduction

Ivermectin Cream (Soolantra) for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015  (Issue 1466)
' tra The FDA has approved a 1% cream formulation of the antiparasitic drug ivermectin (Soolantra ...
The FDA has approved a 1% cream formulation of the antiparasitic drug ivermectin (Soolantra – Galderma) for topical treatment of inflammatory lesions of rosacea. Ivermectin is available in the US in tablets (Stromectol, and generics) for treatment of onchocerciasis and other worm infestations and as a 0.5% lotion (Sklice) for treatment of head lice.
Med Lett Drugs Ther. 2015 Apr 13;57(1466):51-2 | Show Introduction Hide Introduction

In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone

   
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015  (Issue 1466)
, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni ...
The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when either drug is taken with the antiarrhythmic drug amiodarone (Cordarone, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni or with Sovaldi plus simeprevir (Olysio) or the investigational antiviral drug daclatasvir in 9 patients already taking amiodarone; it occurred within 24 hours of starting hepatitis C therapy in 6 patients and within 2-12...
Med Lett Drugs Ther. 2015 Apr 13;57(1466):58 | Show Introduction Hide Introduction

Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
usually continues for at least 3 months.1,2 In patients with nonvalvular atrial fibrillation, dabigatran ...
The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):43-5 | Show Introduction Hide Introduction

Secukinumab (Cosentyx) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
associated with multiple comorbidities.1 Topical preparations, including corticosteroids and vitamin D ...
Secukinumab (Cosentyx – Novartis), an injectable human interleukin (IL)-17A antagonist, has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It is the first IL-17 inhibitor to be approved for any indication in the US.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):45-7 | Show Introduction Hide Introduction